1
|
Miguel RDA, Hirata AS, Salata GC, Apolinário AC, Barroso VM, Ishida K, La Clair JJ, Fenical W, Martins TS, Costa-Lotufo LV, Lopes LB. Topical delivery of seriniquinone for treatment of skin cancer and fungal infections is enabled by a liquid crystalline lamellar phase. Eur J Pharm Sci 2024; 192:106635. [PMID: 37952683 DOI: 10.1016/j.ejps.2023.106635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 10/23/2023] [Accepted: 11/10/2023] [Indexed: 11/14/2023]
Abstract
Seriniquinone (SQ) was initially described by our group as an antimelanoma drug candidate and now also as an antifungal drug candidate. Despite its promising in vitro effects, SQ translation has been hindered by poor water-solubility. In this paper, we described the challenging nanoformulation process of SQ, which culminated in the selection of a phosphatidylcholine-based lamellar phase (PLP1). Liposomes and nanostructured lipid carriers were also evaluated but failed to encapsulate the compound. SQ-loaded PLP1 (PLP1-SQ) was characterized for the presence of sedimented or non-dissolved SQ, rheological and thermal behavior, and irritation potential with hen's egg test on the chorioallantoic membrane (HET-CAM). PLP1 influence on transepidermal water loss (TEWL) and skin penetration of SQ was assessed in a porcine ear skin model, while biological activity was evaluated against melanoma cell lines (SK-MEL-28 and SK-MEL-147) and C. albicans SC5314. Despite the presence of few particles of non-dissolved SQ (observed under the microscope 2 days after formulation obtainment), PLP1 tripled SQ retention in viable skin layers compared to SQ solution at 12 h. This effect did not seem to relate to formulation-induced changes on the barrier function, as no increases in TEWL were observed. No sign of vascular toxicity in the HET-CAM model was observed after cutaneous treatment with PLP1. SQ activity was maintained on melanoma cells after 48 h-treatment (IC50 values of 0.59-0.98 µM) whereas the minimum inhibitory concentration (MIC) against C. albicans after 24 h-treatment was 32-fold higher. These results suggest that a safe formulation for SQ topical administration was developed, enabling further in vivo studies.
Collapse
Affiliation(s)
- Rodrigo Dos A Miguel
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
| | - Amanda S Hirata
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
| | - Giovanna C Salata
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
| | - Alexsandra C Apolinário
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
| | - Vinicius M Barroso
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
| | - Kelly Ishida
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
| | - James J La Clair
- Department of Chemistry and Biochemistry, University of California, La Jolla, San Diego, CA, United States
| | - William Fenical
- Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, La Jolla, San Diego, CA, United States
| | - Tereza S Martins
- Department of Chemistry, Federal University of Sao Paulo, Diadema, SP, Brazil
| | - Leticia V Costa-Lotufo
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil; Department of Human Biology, University of Cape Town, Cape Town, South Africa.
| | - Luciana B Lopes
- Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
| |
Collapse
|
2
|
Lopes LB, Apolinário AC, Salata GC, Malagó ID, Passos JS. Lipid Nanocarriers for Breast Cancer Treatment. Cancer Nanotechnol 2023. [DOI: 10.1007/978-3-031-17831-3_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|
3
|
Bueno CZ, Apolinário AC, Duro-Castano A, Poma A, Pessoa A, Rangel-Yagui CO, Battaglia G. l-Asparaginase Encapsulation into Asymmetric Permeable Polymersomes. ACS Macro Lett 2020; 9:1471-1477. [PMID: 35653665 DOI: 10.1021/acsmacrolett.0c00619] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
This work reports, for the encapsulation of l-asparaginase, an anticancer enzyme into hybrid PMPC25-PDPA70/PEO16-PBO22 asymmetric polymersomes previously developed by our group, with loading capacities with over 800 molecules per vesicle. Enzyme-loaded polymersomes show permeability and capacity to hydrolyze l-asparagine, which is essential to cancer cells. The nanoreactors proposed in this work can be potentially used in further studies to develop novel therapeutic alternatives based on l-asparaginase.
Collapse
Affiliation(s)
- Cecilia Z Bueno
- Department of Biochemical and Pharmaceutical Technology, University of São Paulo, 05508-000 São Paulo, Brazil.,Department of Chemistry, University College London, WC1H 0AJ London, United Kingdom
| | - Alexsandra C Apolinário
- Department of Biochemical and Pharmaceutical Technology, University of São Paulo, 05508-000 São Paulo, Brazil.,Department of Pharmacology, University of São Paulo, 05508-000 São Paulo, Brazil.,Department of Chemistry, University College London, WC1H 0AJ London, United Kingdom
| | - Aroa Duro-Castano
- Department of Chemistry, University College London, WC1H 0AJ London, United Kingdom
| | - Alessandro Poma
- Department of Chemistry, University College London, WC1H 0AJ London, United Kingdom.,Eastman Dental Institute, University College London, WC1X 8LD London, United Kingdom
| | - Adalberto Pessoa
- Department of Biochemical and Pharmaceutical Technology, University of São Paulo, 05508-000 São Paulo, Brazil
| | - Carlota O Rangel-Yagui
- Department of Biochemical and Pharmaceutical Technology, University of São Paulo, 05508-000 São Paulo, Brazil
| | - Giuseppe Battaglia
- Department of Chemistry, University College London, WC1H 0AJ London, United Kingdom.,Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute for Science and Technology (BIST), 08028 Barcelona, Spain.,Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain
| |
Collapse
|
4
|
Apolinário AC, Figueiredo PT, Guimarães AT, Acevedo AC, Castro LC, Paula AP, Paula LM, Melo NS, Leite AF. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta. J Dent Res 2015; 94:95S-102S. [PMID: 25608973 DOI: 10.1177/0022034514567334] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
We hypothesized that mandibular cortical width (MCW) is smaller in children with osteogenesis imperfecta (OI) than in healthy children and that pamidronate can improve the cortical mandibular thickness. The aim of this study was to assess changes in the MCW on dental panoramic radiographs (DPRs) of children with normal bone mineral density (BMD) and with OI. We also compared the MCW of children with different types of OI regarding the number of pamidronate cycles and age at the beginning of treatment. MCW measurements were retrospectively obtained from 197 DPRs of 66 children with OI types I, III, and IV who were in treatment with a comparable dosage of cyclical intravenous pamidronate between 2007 and 2013. The control group had 92 DPRs from normal BMD children. Factorial analysis of variance was used to compare MCW measurements among different age groups and between sexes and also to compare MCW measurements of children with different types of OI among different pamidronate cycles and age at the beginning of treatment. No significant differences in results were found between male and female subjects in both OI and healthy children, so they were evaluated altogether (P > 0.05). There was an increase of MCW values related to aging in all normal BMD and OI children but on a smaller scale in children with OI types I and III. Children with OI presented lower mean MCW values than did children with normal BMD at the beginning of treatment (P < 0.05). A linear model estimated the number of pamidronate cycles necessary to achieve mean MCW values equivalent to those of healthy children. The thinning of the mandibular cortex depended on the number of pamidronate cycles, the type of OI, and the age at the beginning of treatment. DPRs could thus provide a way to identify cyclic pamidronate treatment outcomes in patients with OI.
Collapse
Affiliation(s)
- A C Apolinário
- Campus Universitário Darcy Ribeiro, University of Brasília, Brasília, Brazil
| | - P T Figueiredo
- Oral Radiology, Department of Dentistry, Faculty of Health Science, Campus Universitário Darcy Ribeiro, University of Brasília, Brasília, Brazil
| | - A T Guimarães
- Biostatistics, Biological Sciences Department, State University of West Paraná, Cascavel, Paraná, Brazil
| | - A C Acevedo
- Oral Care Center for Inherited Diseases, Department of Dentistry, Faculty of Health Science, Campus Universitário Darcy Ribeiro, University of Brasília, Brasília, Brazil
| | - L C Castro
- Endocrinology, University of Brasília's Hospital, L2 Norte, Brasília, Brazil
| | - A P Paula
- Hospital de Base of Federal District, Brasília, Brazil
| | - L M Paula
- Oral Care Center for Inherited Diseases, Department of Dentistry, Faculty of Health Science, Campus Universitário Darcy Ribeiro, University of Brasília, Brasília, Brazil
| | - N S Melo
- Oral Pathology, Department of Dentistry, Faculty of Health Science, Campus Universitário Darcy Ribeiro, University of Brasília, Brasília, Brazil
| | - A F Leite
- Oral Radiology, Department of Dentistry, Faculty of Health Science, Campus Universitário Darcy Ribeiro, University of Brasília, Brasília, Brazil
| |
Collapse
|